{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:24Z","timestamp":1792622604449,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jchf.2024.08.007","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T06:04:45Z","timestamp":1725170685000},"page":"1979-1993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Mineralocorticoid Antagonism in Heart\u00a0Failure"],"prefix":"10.1016","volume":"12","author":[{"given":"Joycie","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-4569","authenticated-orcid":false,"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jchf.2024.08.007_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ehjqcco\/qcac088","article-title":"Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990-2019","volume":"9","author":"Wei","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"9","key":"10.1016\/j.jchf.2024.08.007_bib2","article-title":"Impact of mineralocorticoid receptor antagonists in the treatment of heart failure: targeting the heart failure cascade","volume":"15","author":"Jadhav","year":"2023","journal-title":"Cureus"},{"issue":"31","key":"10.1016\/j.jchf.2024.08.007_bib3","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jchf.2024.08.007_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jchf.2024.08.007_bib5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart\u00a0Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jchf.2024.08.007_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.3134","article-title":"Effect of a transitional care model following hospitalization for heart failure: 3-year outcomes of the Patient-Centered Care Transitions in Heart\u00a0Failure (PACT-HF) randomized controlled trial","volume":"26","author":"Averbuch","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jchf.2024.08.007_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jchf.2024.08.007_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.jchf.2024.08.007_bib10","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"41","key":"10.1016\/j.jchf.2024.08.007_bib13","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1093\/eurheartj\/ehac399","article-title":"Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial","volume":"43","author":"Packer","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jchf.2024.08.007_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.jchf.2024.08.007_bib15","first-page":"605","article-title":"Aldosterone antagonism in heart failure","volume":"3","author":"Miller","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.jchf.2024.08.007_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2023","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.jchf.2024.08.007_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jchf.2024.08.007_bib18","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1161\/01.CIR.92.9.2764","article-title":"Guidelines for the evaluation and management of heart failure","volume":"92","author":"Williams","year":"1995","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jchf.2024.08.007_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.1221","article-title":"Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy","volume":"20","author":"Cooper","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jchf.2024.08.007_bib21","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.jchf.2024.08.007_bib22","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jchf.2024.08.007_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jchf.2024.08.007_bib25","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jchf.2024.08.007_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.jchf.2024.08.007_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jchf.2024.08.007_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"23","key":"10.1016\/j.jchf.2024.08.007_bib29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jchf.2024.08.007_bib30","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jchf.2024.08.007_bib31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jchf.2024.08.007_bib32","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease","volume":"13","author":"Lima","year":"2024","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"27","key":"10.1016\/j.jchf.2024.08.007_bib33","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jchf.2024.08.007_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J\u00a0Hum Hypertens"},{"issue":"12","key":"10.1016\/j.jchf.2024.08.007_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN)","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.jchf.2024.08.007_bib36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1253\/circrep.CR-21-0115","article-title":"Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction","volume":"3","author":"Imamura","year":"2021","journal-title":"Circ Rep"},{"issue":"2","key":"10.1016\/j.jchf.2024.08.007_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2024.08.007_bib38","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.08.007_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110239","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis","volume":"196","author":"Charlwood","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.jchf.2024.08.007_bib40","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.08.007_bib41","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jchf.2024.08.007_bib42","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543784.2021.1985462","article-title":"An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension","volume":"30","author":"Pitt","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.jchf.2024.08.007_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jchf.2024.08.007_bib44","article-title":"Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease","volume":"15","author":"Awosika","year":"2023","journal-title":"Cureus"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924006061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924006061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T01:10:24Z","timestamp":1764551424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924006061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2213177924006061"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.08.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Antagonism in Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}